Indications / Non-small cell lung cancer · Breast cancer · Pancreatic cancer · Colorectal cancer · Acute myeloid leukemia · Chronic myeloid leukemia · Multiple myeloma · Glioblastoma · Glioma · Neuroblastoma · Medulloblastoma · Diffuse midline glioma (DIPG) · Ependymoma · Atypical teratoid rhabdoid tumour (AT/RT) · Childhood acute lymphoblastic leukemia · Ewing sarcoma · Osteosarcoma · Rhabdomyosarcoma
Breast cancer
HR+/HER2-, HER2-low and TNBC: CDK4/6, oral SERDs, PI3K pathway and TROP2 ADCs.
ESMO Congress 2026
23–27 Oct 2026, Madrid · Annals of Oncology, vol. 37 supplement
The ESMO 2026 abstract supplement was not in Crossref on 11 Nov 2026 and ESMO's congress platform blocks automated access, so ESMO abstracts here come from web research: each row was found on a published congress report and verified against it.
Headline and verified abstracts
33 abstracts found by Parallel web research on 2026-11-11 and verified: 33 against the saved source excerpt. Rows that could not be verified were dropped. Titles and metadata only; abstract text is not stored.
- LBA14Late-breakingA double-blind placebo controlled randomized phase III trial of fulvestrant and ipatasertib as treatment for HER-2 negative and estrogen receptor positive (ER+) metastatic breast cancer (MBC): Overall survival results of the CCTG/BCT MA.40/FINER studyAndrew D. RedfernCCTG/BCT MA.40/FINERfulvestrantipatasertibMatches source excerptcslide.ctimeetingtech.com
- LBA15Late-breakingAnbenitamab plus albumin-bound docetaxel in patients (pts) with HER2-positive advanced breast cancer (BC): A randomized phase III studyBinghe Xuanbenitamabalbumin-bound docetaxelMatches source excerptcslide.ctimeetingtech.com
- LBA16Late-breakingVIKTORIA-1: Updated results of a randomized, open-label, phase 3 study of gedatolisib (geda) + fulvestrant (fulv) ± palbociclib (palbo) vs standard of care in patients (pts) with HR+/HER2- advanced breast cancer (ABC) (Study 2)Barbara PistilliVIKTORIA-1gedatolisibfulvestrantpalbociclibMatches source excerptcslide.ctimeetingtech.com
- LBA17Late-breakingHER2-PET imaging to predict trastuzumab deruxtecan (T-DXd) efficacy in advanced breast cancer: The phase II PREDICT-HER trialJuan JinPREDICT-HERtrastuzumab deruxtecan (T-DXd)Matches source excerptcslide.ctimeetingtech.com
- LBA23Late-breaking
- LBA24Late-breakingFinal analysis of NRG oncology/NSABP B-42, a randomized, double-blinded, placebo-controlled trial of extended letrozole in postmenopausal women with hormone-receptor positive breast cancer who have completed previous adjuvant therapy with an aromatase inhibitorMatches source excerptcslide.ctimeetingtech.com
- LBA25Late-breaking
- LBA26Late-breakingShort-term preoperative durvalumab for stage I TNBC: First results from the phase II UNLOCK 14 - POP-DURVA trialJoana M. RibeiroUNLOCK 14 - POP-DURVAdurvalumabMatches source excerptcslide.ctimeetingtech.com
- LBA27Late-breaking
- LBA28Late-breaking
- LBA49Late-breakingA DESTINY-Breast09 (DB-)09 analysis of trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for patients (pts) with HER2+ advanced/metastatic breast cancer (a/mBC) and baseline (BL) brain metastases (BMs)Cristina Saura ManichDESTINY-Breast09trastuzumab deruxtecan (T-DXd)pertuzumabtaxanetrastuzumabMatches source excerptcslide.ctimeetingtech.com
- LBA50Late-breakingPANKU-Breast01: Randomized phase III study of izalontamab brengitecan (iza-bren) in previously treated unresectable locally advanced or metastatic (LA/M) hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer (BC)Bo LanPANKU-Breast01izalontamab brengitecan (iza-bren)Matches source excerptcslide.ctimeetingtech.com
- LBA51Late-breaking
- LBA96Late-breakingFirst-line (1L) datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients (pts) with locally recurrent inoperable or metastatic triple-negative breast cancer (mTNBC) for whom immunotherapy was not an option: Exploratory analysis of pts with brain metastases in TROPION-Breast02Rebecca A. DentTROPION-Breast02NCT05374512datopotamab deruxtecan (Dato-DXd)nab-paclitaxelcapecitabineeribulin mesylateMatches source excerptcslide.ctimeetingtech.com
- 1842OOral presentationEfficacy and safety of atirmociclib (ATI) + fulvestrant (FUL) in patients (pts) with HR+/HER2– advanced/metastatic breast cancer (mBC) who progressed on prior CDK4/6 inhibitor (CDK4/6i) in a randomized phase 2 study (FOURLIGHT-1)Antonio GiordanoFOURLIGHT-1atirmociclib (ATI)fulvestrant (FUL)Matches source excerptcslide.ctimeetingtech.com
- 1RORapid oralOverall survival from the phase 3 postMONARCH trial of abemaciclib + fulvestrant vs placebo + fulvestrant for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor + endocrine therapyKevin KalinskypostMONARCHabemaciclibfulvestrantMatches source excerptcslide.ctimeetingtech.com
- 2RORapid oralRetrospective exploratory biomarker (BM) analyses from evERA breast cancer (BC): A phase III trial of giredestrant (GIRE) + everolimus (E) in patients (pts) with oestrogen receptor-positive, HER2-negative advanced BC (ER+, HER2– aBC) in the post-CDK4/6 inhibitor (i) settingMatches source excerptcslide.ctimeetingtech.com
- 3RORapid oral
- 4RORapid oral
- 5RORapid oralSafety and efficacy of SYS6043, a novel B7-H3—targeting antibody-drug conjugate, in patients with advanced breast cancerHongxia WangSYS6043Matches source excerptcslide.ctimeetingtech.com
- 538RORapid oralPatient (pt)-reported outcomes (PROs) from the Phase III lidERA Breast Cancer (BC) trial of giredestrant (GIRE) in pts with oestrogen receptor-positive, HER2-negative early BC (ER+, HER2– eBC)Gustavo WerutskylidERAgiredestrant (GIRE)Matches source excerptcslide.ctimeetingtech.com
- 539RORapid oralPatient-reported outcomes (PROs) from DESTINY-Breast05: Health-related quality of life (HRQoL) with trastuzumab Deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients (Pts) with high-risk HER2-positive early breast cancer (eBC)Carlos H. BarriosDESTINY-Breast05trastuzumab deruxtecan (T-DXd)trastuzumab emtansine (T-DM1)Matches source excerptcslide.ctimeetingtech.com
- 540RORapid oral
- 542RORapid oralPrognostic impact of postoperative ctDNA surveillance on relapse-free survival and molecular lead time in high-risk breast cancer: JCOG1204A1Yukinori OzakiJCOG1204A1Matches source excerptcslide.ctimeetingtech.com
- 543RORapid oralDESTINY-Breast11: MRI-assessed objective responses during neoadjuvant treatment (NAT) with trastuzumab deruxtecan (T-DXd) followed by paclitaxel + trastuzumab + pertuzumab (THP) vs dose-dense doxorubicin + cyclophosphamide followed by THP (ddAC-THP) in HER2+ early breast cancer (eBC)Jean-Francois BoileauDESTINY-Breast11NCT05113251trastuzumab deruxtecan (T-DXd)paclitaxeltrastuzumabpertuzumabMatches source excerptcslide.ctimeetingtech.com
- 544RORapid oralFinal analysis of the GIM3 FATA trial: Treatment schedule and three aromatase inhibitors (AIs) comparison in postmenopausal HR-positive (HR+) early breast cancer (eBC)Pietro De PlacidoGIM3 FATAanastrozoleexemestaneletrozoletamoxifenMatches source excerptcslide.ctimeetingtech.com
- 545RORapid oral
- 1766RORapid oralHealth-related quality of life from HER2CLIMB-05: A phase 3 study of tucatinib versus placebo in combination with trastuzumab and pertuzumab as 1L maintenance therapy for HER2+ mBCVeronique C. DierasHER2CLIMB-05tucatinibtrastuzumabpertuzumabMatches source excerptcslide.ctimeetingtech.com
- 1767RORapid oral
- 1768RORapid oralRadiation therapy followed by intrathecal (IT) trastuzumab/pertuzumab in the management of HER2+ breast leptomeningeal metastasis: Results from a phase II multi-institutional study, (INSPIRE-LM)Kamran AhmedINSPIRE-LMtrastuzumabpertuzumabMatches source excerptcslide.ctimeetingtech.com
- 1769RORapid oralCTC characterization with the DETECT CTC score predicts therapy response in triple-positive aBC: Translational results of the phase III DETECT V studyKerstin PfisterDETECT VMatches source excerptcslide.ctimeetingtech.com
- 4639RORapid oralFinal OS analysis of sacituzumab tirumotecan versus chemotherapy in previously treated locally recurrent or metastatic triple-negative breast cancer: Phase III OptiTROP-Breast01Ying Fan (presented by Man Li)OptiTROP-Breast01sacituzumab tirumotecanMatches source excerptcslide.ctimeetingtech.com
- 4640RORapid oralBulumtatug fuvedotin (BFv, 9MW2821), a nectin-4–directed antibody-drug conjugate (ADC), in patients with locally advanced or metastatic triple negative breast cancer (la/mTNBC) previously treated with topoisomerase I inhibitor (TopI)-based ADCs: Results from a phase 2 studyMatches source excerptcslide.ctimeetingtech.com
Indexed in Crossref
The ESMO Congress 2026 supplement (Annals of Oncology, vol. 37 supplement) was not in Crossref when last checked on 11 Nov 2026. The verified abstracts above come from web research instead.